{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:22:34Z","timestamp":1760080954425},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1038\/s41571-024-00890-2","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T12:02:08Z","timestamp":1713182528000},"page":"487-488","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinoma"],"prefix":"10.1038","volume":"21","author":[{"given":"David H.","family":"Aggen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan E.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,15]]},"reference":[{"key":"890_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45714-0","volume":"15","author":"M Rijnders","year":"2024","unstructured":"Rijnders, M. et al. Gene-expression-based T-cell-to-stroma enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer. Nat. Commun. 15, 1349 (2024).","journal-title":"Nat. Commun."},{"key":"890_CR2","doi-asserted-by":"publisher","first-page":"LBA443","DOI":"10.1200\/JCO.2023.41.6_suppl.LBA443","volume":"41","author":"MD Galsky","year":"2023","unstructured":"Galsky, M. D. et al. Extended follow-up results from the CheckMate 274 trial. J. Clin. Oncol. 41, LBA443 (2023).","journal-title":"J. Clin. Oncol."},{"key":"890_CR3","doi-asserted-by":"publisher","first-page":"LBA531","DOI":"10.1200\/JCO.2024.42.4_suppl.LBA531","volume":"42","author":"AB Apolo","year":"2024","unstructured":"Apolo, A. B. et al. AMBASSADOR Alliance A031501: phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation. J. Clin. Oncol. 42, LBA531 (2024).","journal-title":"J. Clin. Oncol."},{"key":"890_CR4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51, 202\u2013206 (2019).","journal-title":"Nat. Genet."},{"key":"890_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24112-w","volume":"12","author":"R Banchereau","year":"2021","unstructured":"Banchereau, R. et al. Molecular determinants of response to PD-L1 blockade across tumor types. Nat. Commun. 12, 3969 (2021).","journal-title":"Nat. Commun."},{"key":"890_CR6","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"890_CR7","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","volume":"25","author":"T Powles","year":"2019","unstructured":"Powles, T. et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat. Med. 25, 1706\u20131714 (2019).","journal-title":"Nat. Med."},{"key":"890_CR8","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"key":"890_CR9","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N. Engl. J. Med. 390, 875\u2013888 (2024).","journal-title":"N. Engl. J. Med."},{"key":"890_CR10","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","volume":"29","author":"MD Galsky","year":"2023","unstructured":"Galsky, M. D. et al. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. Nat. Med. 29, 2825\u20132834 (2023).","journal-title":"Nat. Med."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00890-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00890-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00890-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T13:05:00Z","timestamp":1719234300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00890-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["890"],"URL":"https:\/\/doi.org\/10.1038\/s41571-024-00890-2","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,15]]},"assertion":[{"value":"15 April 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.A. has acted as a consultant and\/or advisor of Astellas, BMS, Century Therapuetics and has received research funding from Astellas, Merck and Seagen. J.R. has acted as a consultant and\/or advisor of Aadi Biosciences, Aktis, Alligator Biosciences, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, BMS, Boehringer Ingelheim, Century Therapeutics, EMD-Serono, Gilead, Hengrui, Imvax, Janssen, Loxo, Merck, Pfizer, Seagen and Tyra Biosciences and has received research funding from Acrivon, Astellas, AstraZeneca, Bayer, Loxo and Seagen.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}